InvestorsHub Logo
Followers 51
Posts 9121
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Sunday, 11/06/2022 1:23:22 AM

Sunday, November 06, 2022 1:23:22 AM

Post# of 13510
The good news is that RSV vaccines are on the way:

Moderna Inc. says its vaccine for respiratory syncytial virus, better known as RSV, could be ready for commercialization as soon as next year.

The Cambridge drugmaker is currently running a Phase 3 trial of its mRNA-based RSV vaccine. Data is expected sometime this winter; if it meets expectations, then Moderna could launch it before the fall 2023 sick season, executives said on the company's third-quarter earnings call Thursday morning.

$MRNA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News